Genenta Science S.p.A. (SAEN) shareholders
SAENNasdaqBiological Products, (No Diagnostic Substances)
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Apr 1, 2026Score 6/30
$0.58−0.02 (-3.83%)
Close on Nov 17, 2026Market cap $13.52MP/E –Yield –
Ownership
Who owns Genenta Science S.p.A.'s shares
Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Marco Nuzzo Joint filing with Luigi Naldini (11.50%), Bernhard Gentner (11.50%) and 8 more | 5,543,910 | 11.50% | 13D (active) amendment | May 29, 2026 |
| Pierluigi Paracchi | 2,302,516 | 9.80% | 13G (passive) amendment | Jan 25, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Pierluigi Paracchi | Chief Executive Officer, Director, 10% owner | 27,000 | 0.12% | May 5, 2026 |
| Francesco Galimi | CMO& Head of Development, Director | 0 | – | Apr 1, 2026 |
| Richard B. Slansky | Chief Financial Officer | 2,200 | 0.01% | Apr 1, 2026 |
| Giacomoantonio Paracchi | Director | 0 | – | Apr 1, 2026 |
| Armon Sharei | Director | 0 | – | Apr 1, 2026 |
| Miguel Maria Mutti | Director | 0 | – | Apr 1, 2026 |
See a number that looks wrong?